MannKind | MNKD - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Adma Biologics USD 232.29M 5.59M 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Halozyme Therapeutics USD 118.52M 741K 2026-03
Insmed USD 216.52M 2.27M 2026-03
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
MacroGenics USD 63.56M 241K 2026-03
MannKind USD 308.91M 1.07M 2026-03
Merck USD 2.47B 12.72M 2025-12
Minerva Neurosciences USD 1000 0 2024-09
Novavax USD 162.58M 106K 2025-12
Novo Nordisk DKK 4.44B 3.99B 2025-06
Pfizer USD 5.7B 13M 2026-03
Sanofi EUR 1.21B 8.25M 2026-03
Xencor USD 74.06M 2.19M 2026-03